Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019
May 23 2019 - 6:45AM
Business Wire
Case broadcast live to thousands of EuroPCR
attendees from Clinique Pasteur in France
Corindus Vascular Robotics, Inc. (“Corindus” or
the “Company”) (NYSE American: CVRS), a leading developer of
precision vascular robotics, announced today its CorPath® GRX
System was successfully used to perform a live complex
robotic-assisted percutaneous coronary intervention (PCI) at the
EuroPCR 2019 Conference in Paris, France on Wednesday, May 22,
2019.
Interventional Cardiologist, PCR Vice-Chairman, and Course
Director of EuroPCR, Dr. Jean Fajadet performed the procedure from
Clinique Pasteur in Toulouse, France. It was broadcast live to
EuroPCR attendees, marking the first time a robotic procedure using
CorPath GRX was performed and broadcast live in Europe. Dr. Fajadet
is the co-director of the interventional cardiology unit at
Clinique Pasteur, which became the first site in Europe to adopt
the Company's most advanced vascular robotic technology when it
installed the CorPath GRX System this year.
“As robotic capabilities continue to advance, we are very
pleased to share the latest developments in CorPath GRX with the
attendees at EuroPCR,” said Mark Toland, President and Chief
Executive Officer of Corindus. “Dr. Fajadet is a pioneer of this
technology in Europe and understands our ultimate vision of
enhancing patient care through the advancement of our technology.
In just a few short months, he has established his facility as a
leader in vascular robotics and has demonstrated the positive
impact of a high-tech care model to the clinical community in
Europe.”
The CorPath System is the world’s only U.S. Food and Drug
Administration (FDA) cleared and CE marked robotic platform for
percutaneous coronary intervention (PCI) and peripheral vascular
intervention (PVI) procedures. CorPath GRX received CE mark for
neurovascular intervention in April 2019, broadening the
application of the CorPath GRX System to treat all vascular beds in
Europe.
“CorPath GRX offers the level of precision and control necessary
to perform even the most complex PCI procedures,” said Dr. Fajadet.
“The live case went exactly as planned. I was able to complete the
procedure with control of all interventional devices and imaging
equipment from the control room, providing my patient with
high-quality care while protecting myself and the cath lab team. I
am pleased to share this technology with my peers to demonstrate
how far it has come, and the promising future it may provide
patients.”
EuroPCR, which is the annual meeting of the European Association
of Percutaneous Cardiovascular Interventions, is celebrating its
30th anniversary and will host more than 11,000 participants from
across the globe. For attendees interested in an exclusive
opportunity to gain firsthand experience with the latest smart
procedural automation technology available on the CorPath GRX
System, register here and visit Corindus at booth M49 through
Friday, May 24, 2019.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics is a global technology leader in
robotic-assisted vascular interventions. The Company’s CorPath®
platform is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and vascular procedures. CorPath
GRX is the second generation robotic-assisted technology offering
enhancements to the platform by adding important key upgrades that
increase precision, improve workflow, and extend the capabilities
and range of procedures that can be performed robotically. We are
focused on developing innovative robotic solutions to revolutionize
treatment of emergent conditions by providing specialized and
timely medical care to patients around the world. For additional
information, visit www.corindus.com, and follow @CorindusInc.
Forward Looking Statements
Statements made in this release that are not statements of
historical or current facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Corindus to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. Accordingly, readers should not place undue reliance on
any forward-looking statements. In addition to statements that
explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as "believes," "belief," "expects,"
"estimates," "intends," "anticipates" or "plans" to be uncertain
and forward-looking. Forward-looking statements may include
comments as to Corindus’ beliefs and expectations as to future
events and trends affecting its business and are necessarily
subject to uncertainties, many of which are outside Corindus’
control.
Examples of such statements include statements regarding or such
as:
- Our ultimate vision of enhancing
patient care through the advancement of our technology; and
- The participants expected at the
European Association of Percutaneous Cardiovascular
Interventions.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are described in the sections titled "Risk Factors" in the
Company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, including,
but not limited to the following: our ability to expand our
technology platform and achieve the advances necessary for
telestenting and remote procedures, including in humans; our
ability to expand our technology platform for use in other segments
of the vascular intervention market, including neurointerventional
and other more complex cardiac interventions; obtaining necessary
regulatory approvals for the use on humans and marketing of our
products in the United States and in other countries, including for
stroke and other neurovascular interventions; the rate of adoption
of our CorPath System and the rate of use of our cassettes; risks
associated with market acceptance, including pricing and
reimbursement; our ability to enforce our intellectual property
rights; our need for additional funds to support our operations;
our ability to manage expenses and cash flow; factors relating to
engineering, regulatory, manufacturing, sales and customer service
challenges; potential safety and regulatory issues that could slow
or suspend our sales; and the effect of credit, financial and
economic conditions on capital spending by our potential customers.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More
information is available on Corindus' website at
http://www.corindus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190523005210/en/
Corindus:Media Contact:Matter for CorindusJessica
WolterT:
978-518-4536corindus@matternow.comwww.matternow.comInvestor
Contact:Lisa WilsonIn-Site Communications, Inc.T:
917-543-9932ir@corindus.com
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jul 2023 to Jul 2024